CC
ELVN icon

Caxton Corporation’s Enliven Therapeutics ELVN Stock Holding History

Caxton Corporation’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,097
Closed -$268K – 12
2025
Q3 		$268K Hold
13,097
– – 1.17% 5
2025
Q2 		$263K Buy
+13,097
New +$248K 2.67% 4

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Caxton Corporation's ELVN Position: Q4 2025 in Review

Caxton Corporation sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 13,097 shares — an estimated $268K sold.

Caxton Corporation first reported a position in ELVN in Q2 2025 and held it in 2 quarters. The position peaked at $268K in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Caxton Corporation reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Caxton Corporation sold 13,097 Enliven Therapeutics shares in Q4 2025, an estimated $268K.
  • Caxton Corporation first reported a position in Enliven Therapeutics in Q2 2025 and held it in 2 quarters.
  • Caxton Corporation's Enliven Therapeutics position peaked at $268K in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Caxton Corporation's 13F filing for Q4 2025, filed 13 Feb 2026.